comparemela.com

Latest Breaking News On - Novel pharma - Page 1 : comparemela.com

GC Biopharma/Novel Pharma s Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A..

United statesSouth koreaSoult ukpyolsiHeparann sulfataseSohee kimPharma sanfilippoRachel kimYelin junGc biopharma corpGreen cross corporationNovel pharma incNovel pharmaSanfilippo syndrome typeOrphan drug designationRare pediatric disease designationSyndrome type

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma s Treatment for Sanfilippo Syndrome (Type A)

/PRNewswire/ GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its.

South koreaYelin junRachel kimSohee kimEuropean medicines agencyGc biopharma corpPrnewswire gc biopharma corpGreen cross corporationOrphan drug designationEnzyme replacement therapySanfilippo syndromeRare pediatric diseaseNovel pharmaGc biopharmaHealth care amp hospitalsMedical pharmaceuticals

vimarsana © 2020. All Rights Reserved.